我是肿瘤学的全球主管, 澳门葡京网赌游戏肿瘤事业部的医疗部门, 帮助推动澳门葡京赌博游戏重新定义癌症治疗的愿景.  澳门葡京赌博游戏通过强有力的证据生成来推进癌症治疗的实践, 科学伙伴关系和帮助重新构想未来的癌症治疗模式.  Our science-focused approach along with evidence builds the confidence in the decision making process for clinicians and patients.

Prior to my current role, I led AstraZeneca’s global research and development in breast cancer. 作为工作的一部分, 我领导了澳门葡京赌博游戏乳腺癌战略的制定和执行, 建立肿瘤委员会模型, and designed and established our industry leading clinical development program in Breast Cancer.

在担任了近15年的肿瘤内科医生之后，我加入了澳门葡京网赌游戏, 重点是乳腺癌和肺癌. 我的研究和教育领导能力获得了国际认可, which included being principal investigator for many pivotal trials in breast cancer including several practice-changing Phase III trials. My work has been published in more than 125 peer-reviewed manuscripts including in the New England Journal of Medicine, The Lancet, 临床肿瘤与癌症杂志. I have also led and created numerous innovative educational projects in oncology and won several teaching and mentoring awards.

除了对临床研究和临床护理的影响, 作为临床医生和癌症研究先驱的导师，我为自己的角色感到自豪. Over my career, 我指导过100多名住院医生, fellows and faculty and it truly is a great honour to see many of them develop to become leaders in Cancer centres around the globe.

我主持过, co-chaired or been a member of many regional and national health services cancer leadership committees in Canada and international cancer conference leadership committees, 致力于在全球范围内改善患者的治疗效果.

After receiving a medical degree and postgraduate training in internal medicine and medical oncology at the 阿尔伯塔大学 in Canada, 我在南加州大学获得了医学教育硕士学位. 我在乳腺癌方面的培训包括在多伦多大学获得奖学金.

Throughout my career I have been driven to make changes that bring real benefits for people with cancer. We are at an unprecedented time where the cancer care landscape is on the verge of being completely transformed, and I believe the team here at AstraZeneca will have a critical role in shaping our vision and working with the oncology community to make it a reality. Our best-in-class research programs covering areas such as antibody drug conjugates, DNA损伤反应, immuno-oncology, 肿瘤驱动因素和耐药性, as well as our digital expertise and collaborative approach put us in a unique place to make our ambition a reality.

2006年世界前25名年轻乳腺肿瘤学家

Future Forum Award recognizing young oncologists who will be future leaders in breast cancer

优秀教学奖(2005、2007、2011)

医学系, Faculty of Medicine, University of Toronto, 内科肿瘤科

杰出校友奖

阿尔伯塔大学

CURRENT ROLE

澳门葡京网赌游戏的高级副总裁，全球肿瘤医学主管

2019-2021

Served as Head of Breast Cancer Research Strategy and Global Clinical Head for Breast Cancer at AstraZeneca, 负责领导公司在乳腺癌方面的研发工作

2015-2019

Led the growth of the department and launched the build of the New Calgary Cancer Centre, one of the largest comprehensive cancer care facilities in North America during term as Professor and Head of the Department of Oncology at the University of Calgary and Medical Director of the Tom Baker Cancer Centre

2004-2015

曾在多伦多大学任职, 最近担任副教授, 医学系

帕博西尼和富维司汀治疗晚期乳腺癌的总生存率

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H. N Engl J Med. 2018年11月15日;379(20):1926-36.

http://www.nejm.org/doi/full/10.1056/NEJMoa1810527

Palbociclib plus endocrine therapy in older women with HR+/HER2–advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

Rugo HS, Turner NC, Finn RS, Joy AA， Verma S，黄晓明，孙伟，金树华，李建平. 刘建军，刘建军，刘建军. Eur J Cancer. 2018年9月1日;101:123-33.

http://www.ejcancer.com/article/S0959-8049(18)30908-0/fulltext

Health-related quality of life of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

Verma S, O ' shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. 乳腺癌治疗. 2018 Aug1; 170 (3): 535 - 45.

http://link.springer.com/article/10.1007%2Fs10549-018-4769-z

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

disamras V, Miles D， Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Lancet Oncol. 2017年6月,18 (6):732 - 742.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30312-1/fulltext

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, 安慰剂对照, III期研究(PALOMA-3)

Verma S, Bartlett CH, Schnell P, Demichele AM, Loi S, Ro J, Colleoni M, Iwata  H, Harbeck N, Cristofanilli博士米, Zhang K, Thielse A, Turner NC, Rugo HS. Oncologist. 2016年10月,21 (10):1165 - 75.

http://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2016-0097

曲妥珠单抗Emtansine治疗her2阳性晚期乳腺癌

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, 艾米莉亚研究小组, N Engl J Med. 2012年11月8日;367(19):1783-91.

http://www.nejm.org/doi/full/10.1056/NEJMoa1209124

Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey

Verma S， Provencher L, Dent R， Curr Oncol. 2011年8月3日;18(4):180-90.

http://current-oncology.com/index.php/oncology/article/view/913

 

患者对芳香化酶抑制剂辅助治疗的依从性

Verma S， Madarnas Y, Sehdev S, Martin G, Bajcar J. Curr Oncol. 2011年5月;18增刊1:S3-9.

http://current-oncology.com/index.php/oncology/article/view/899

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

Verma S, Ewer MS. Ann Oncol. 2011年5月,22 (5):1011 - 8.

http://www.annalsofoncology.org/article/S0923-7534(19)38535-7/fulltext

Veeva ID: Z4-37225
筹备日期:2021年11月